CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
Open Access
- 20 December 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1), e000624
- https://doi.org/10.1136/jitc-2020-000624
Abstract
Background CD40 is a compelling target for cancer immunotherapy, however, attempts to successfully target this pathway have consistently been hampered by dose-limiting toxicity issues in the clinic that prevents the administration of efficacious doses. Methods Here, using cytokine and cytokine receptor depletion strategies in conjunction with a potent CD40 agonist, we investigated mechanisms underlying the two primary sources of CD40 agonist-associated toxicity, hepatotoxicity and cytokine release syndrome (CRS). Results We demonstrate that CD40 agonist -induced hepatotoxicity and CRS are mechanistically independent. Historical data have supported a role for interleukin-6 (IL-6) in CRS-associated wasting, however, our findings instead show that an inflammatory cytokine network involving TNF, IL-12p40, and IFNγ underlie this process. Deficiency of TNF or IFNγ did not influence CD40-induced hepatitis however loss of IL-12p40 significantly decreased circulating concentrations of liver enzymes and reduced the frequency of activated CD14+MHCII+ myeloid cells in the liver, indicating a role for IL-12p40 in liver pathology. Conclusions As clinical research programs aim to circumnavigate toxicity concerns while maintaining antitumor efficacy it will be essential to understand which features of CD40 biology mediate antitumor function to develop both safe and efficacious agonists.Keywords
Funding Information
- Pfizer, Inc.
This publication has 24 references indexed in Scilit:
- Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trialsImmunopharmacology and Immunotoxicology, 2014
- Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of CancerCancer Immunology Research, 2014
- Aging predisposes to acute inflammatory induced pathology after tumor immunotherapyThe Journal of Experimental Medicine, 2013
- Agonistic CD40 Antibodies and Cancer TherapyClinical Cancer Research, 2013
- Characterization of two F4/80-positive Kupffer cell subsets by their function and phenotype in miceJournal of Hepatology, 2010
- Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulationJournal of Translational Medicine, 2009
- The role of CD40 and CD154/CD40L in dendritic cellsSeminars in Immunology, 2009
- Isolation of murine intrahepatic immune cells employing a modified procedure for mechanical disruption and functional characterization of the B, T and natural killer T cells obtainedClinical and Experimental Immunology, 2008
- Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal AntibodyJournal of Clinical Oncology, 2007
- Differential Activity of IL-12 and IL-23 in Mucosal and Systemic Innate Immune PathologyImmunity, 2006